RNA Analysis/Transcriptomics Market Size, Share and Trends Analysis, By Product Type (Instruments, Software & Bioinformatics, and Services) By Technology (NGS, qPCR, Microarrays and DSP), By Application, By End-Use, and By Region, Forecast 2026-2033

RNA Analysis/Transcriptomics Market Overview and Key Insights:

RNA Analysis/Transcriptomics market size reached USD 6.44 Billion in 2025 and is expected to register a revenue CAGR of 14.8% during the forecast period. Transcriptomics is the study of the transcriptome, which is the collection of all ribonucleic acid (RNA) that exists in a sample at any particular time. Transcriptome comparison enables the identification of genes that differ in expression across cell populations or in response to different treatments.

Market Drivers:

Rising demand for precision medicine is a key driver driving the market revenue growth. The field of medicine is undergoing a transformative shift toward personalization, driven by the realization that each patient’s genetic and molecular makeup is unique. RNA analysis/transcriptomics plays an important role in this paradigm by providing detailed molecular profiles that can guide personalized therapeutic strategies. Transcriptomics identifies indicators that predict drug response, allowing for more effective therapy selection for individual patients.

For example, transcriptome data can identify which breast cancer patients are most likely to benefit from hormone therapy or tailored treatments, eliminating the need for trial and error and minimizing side effects. Transcriptomics has the potential to transform healthcare as the discipline develops, enabling patients all around the world to receive tailored treatment. The full potential of transcriptomics to improve patient outcomes and revolutionize medical practice will be achieved via ongoing research and innovation.

On March 2026, Alithea Genomics, an expanding leader in large-scale RNA sequencing and transcriptomics, announced the completion of its seed funding round with an additional CHF 3 million (USD 3.9 million). The profits will be utilized to speed commercialization of the new 1536-well MERCURIUSTM DRUG-seq kits, unlocking the promise of employing cell transcriptomics in primary drug screening and exploratory toxicology. Alithea will also use the resources to accelerate new technology development and create unique transcriptome data assets to support the industry’s AI/ML aspirations.

Market Opportunity:

Artificial Intelligence (AI) & bioinformatics advancements act as opportunity for RNA analysis/transcriptomics market. The rapid adoption of high-throughput sequencing technologies and multi-omics approaches has significantly accelerated the generation of genomic, transcriptomic, proteomic, and single-cell multimodal datasets, leading to an exponential rise in biological data. With the integration of deep neural networks, machine learning (ML) has advanced into deep learning (DL), enabling the extraction of complex patterns from unstructured data. This enhances analytical capabilities in areas such as classification, transcriptional network regulation, mRNA splicing, and spatiotemporal gene expression dynamics.

From a precision medicine standpoint, deep neural networks trained on labeled datasets support supervised learning applications. For example, decentralized AI frameworks like Swarm learning have been successfully applied as disease classification tools, aiding in the diagnosis of conditions such as leukemia, tuberculosis, and COVID-19 using blood transcriptome data.

On January 2026, Illumina, Inc. introduced the world’s biggest genome-wide genetic perturbation dataset, which is being developed to expedite drug development across the pharmaceutical ecosystem using AI. The Illumina Billion Cell Atlas is the first phase in a three-year program to create a 5 billion cell atlas, which will be the most comprehensive picture of human disease biology to date. The Atlas’ size is only possible because to the capacity of the Illumina Single Cell 3′ RNA prep platform, which can collect millions of individual cells in a single experiment. The Atlas will create 20 petabytes of single-cell transcriptome data per year.

Recent Trends:

Emerging trends include single-cell RNA sequencing (scRNA-seq), spatial transcriptomics, cloud-based bioinformatics platforms, automation & lab-on-a-chip technologies, and synthetic biology & RNA engineering.

Single-cell RNA sequencing (scRNA-seq) techniques can examine sequence data from individual cells, exposing population variation and enabling for extremely detailed analysis of cell circumstances and transformations. In cancer research, scRNA-Seq has proven indispensable for detecting uncommon tumor cells, such as malignant tumor cells within a tumor or hyper-responsive immune cells within an otherwise homogeneous group.

It has been extremely useful in the research of carcinogenesis, allowing us to gain insight into the genetic and molecular properties of various phases of tumor formation, from precancerous lesions to aggressive tumors and metastases. Personalized therapies to metastatic disease, such as tailored immunotherapy, have proven to be the most effective.

On February 2025, Scale Biosciences, a pioneer in innovative and scalable single cell analysis solutions, has announced the release of its QuantumScale Single Cell RNA kits, a suite of next-generation single cell products capable of capturing and processing 84,000 to 4 million cells without the use of specialized partitioning equipment. The breakthrough platform, based on the company’s Quantum Barcoding technology, is the most cost-effective single cell solution on the market in terms of per cell, sample, and experiment, and it provides a single simple and efficient workflow for any size project or research program.

Restraints & Challenges:

<p>ScRNA-seq provides improved resolution and visualization of differential gene expressions across cell types and stages. However, this results in data that is very variable, contains errors, and has background noise. Amplification bias can occur due to stochastic fluctuation in amplification efficiency, resulting in a skewed representation of specific genes and an overestimation of their expression levels. ScRNA-seq necessitates specialised techniques and data analysis approaches to account for technical and biological variability at the single-cell level.

It can capture many cells in a single droplet, resulting in doublets that can confuse downstream processing and misidentify cell types. ScRNA-seq data demands stringent quality control procedures, such as cell viability, library complexity, and sequencing depth. Poor-quality samples might lead to incomplete coverage, technical noise, and biased conclusions.

Product Type Segment Insights and Analysis:

Based on the product type, RNA analysis/transcriptomics market is segmented into instruments, software & bioinformatics, and services.

Instruments segment contributed the largest market share in 2025. It is further sub segmented into sequencers, PCR systems, and microarray scanners. RNA sequencing is presently the dominant approach for transcriptome profiling and analysis, outperforming microarray analysis due to its higher sensitivity, broader dynamic range, transcript discovery capability, and lack of the need for pre-existing sequence knowledge. It offers tremendous advantages over existing transcriptome technologies. To begin, RNA-Seq is extremely sensitive, detecting and quantifying nearly all transcripts in the cells, including unusual transcripts with only a few copies. Its detection range spans six orders of magnitude.

In February 2026, Parse Biosciences, a QIAGEN company and the leading provider of scalable and accessible single-cell sequencing solutions, has announced the release of the new Evercode Whole Transcriptome v4 product line, which provides increased scalability, higher sensitivity, and a streamlined workflow for single-cell RNA sequencing. Evercode v4 has amazing scalability, supporting up to five million cells and 384 samples in a single run. This allows researchers to design big experiments while preserving sample resolution. The improved chemistry enhances gene detection per cell while using fewer sequencing reads, lowering total sequencing costs.

Technology Segment Insights and Analysis:

Based on the technology, RNA analysis/transcriptomics market is segmented into Next-Generation Sequencing (NGS), Polymerase Chain Reaction (qPCR), microarrays, and Digital Spatial Profiling (DSP).

Next-Generation Sequencing (NGS) segment contributed the largest market share in 2025. The development of high-throughput next-generation sequencing (NGS) has transformed transcriptomics by allowing RNA analysis via complementary DNA (cDNA). RNA-Seq offers a more thorough and quantitative understanding of gene expression, alternative splicing, and allele-specific expression. Recent developments in the RNA-Seq methodology, from sample preparation to sequencing platforms to bioinformatic data interpretation, have allowed for deep transcriptome profiling and the investigation of many physiological and clinical conditions.

As laboratory procedures advance to allow for the sequencing of small amounts of RNA, complicated statistical approaches will be required to distinguish between technical noise and genuine biological variation. These advances will make it easier to analyze transcriptomes in rare cell types and cell states, allowing researchers to reconstruct biological networks that operate at the cellular level.

On November 2024, Lexogen, a pioneer in NGS services, has introduced a simplified Blood RNA-Seq Service to speed up drug discovery from whole blood or biofluids. Lexogen’s established blood transcriptomics products, such as CORALL for Blood and QuantSeq for Blood, provide efficient globin removal and robust processes for complete whole transcriptome sequencing and cost-effective gene expression profiling from blood. QuantSeq-Pool for Blood technology enables exceptional scalability of up to 36,864 samples through sample barcoding and early pooling.

Application Segment Insights and Analysis:

Based on the application, RNA analysis/transcriptomics market is segmented into drug discovery & development, clinical diagnostics, biomarker discovery, toxicogenomics, and personalized medicine.

Drug discovery & development segment contributed the largest market share in 2025. RNA-Seq has swiftly evolved into a valuable tool for transcriptome profiling and gene expression research, making it essential for the development of next-generation medicines. It aids in the discovery of new functional genes, provides insight into the spatial and temporal expression of specific tissue or cellular genes, and allows for the exploration of short RNAs, all of which are commonly utilized in disease diagnostics, drug screening, and other applications.

Small RNA-Seq, also known as microRNA-Seq, is an excellent method for identifying putative miRNA drivers of drug resistance since it allows for a comparison of miRNA expression profiles in drug-resistant and non-resistant cells.

On November 2025, SPT Labtech, a global pioneer in the design and development of laboratory automation and liquid handling solutions, has announced a collaboration with Alithea Genomics to create an automated single-cell transcriptomics solution. The collaboration combines Alithea Genomics’ MERCURIUS FLASH-seq, an ultra-sensitive single-cell RNA-seq technology, with SPT Labtech’s firefly liquid handling platform to create a scalable and reproducible transcriptomics research methodology. Single-cell transcriptomics is a fast-emerging discipline that is propelling discoveries in cell biology, immunology, and drug development.

Geographical Outlook:

RNA analysis/transcriptomics market is strategically segmented by geography to provide a comprehensive understanding of regional market dynamic. Discover demand analysis, emerging trends, and growth opportunities shaping market performance across different region and countries.

North America RNA Analysis/Transcriptomics Market:

North America is registered to have highest market share in RNA analysis/transcriptomics market in 2025. This is mainly driven by continuous investment in genomics, oncology, and precision medicine, strong presence of leading universities and research centers, and rising demand of clinical diagnostics. RNA Sequencing Analysis is the high-throughput sequencing of RNA to better understand gene expression patterns and control in a variety of biological situations. RNA Sequencing Analysis has several advantages, including improved disease diagnosis and treatment, such as cancer, as well as advances in agricultural biotechnology. Its widespread application promotes innovation in medication development and genomic research, resulting in economic growth in the biotechnology sector.

On July 2025, New England Biolabs (NEB) has announced the release of the NEBNext Low-bias Small RNA Library Prep Kit, which is intended to reduce biased representation of small RNA species in sequencing data. This next-generation small RNA preparation process is faster, less biased, and accepts a wider variety of inputs than current commercial kits. This kit was created to produce RNA libraries with more realistic representations of tiny RNA species.</p>

Asia Pacific RNA Analysis/Transcriptomics Market:

Asia Pacific is expected to register the fastest growth rate during the forecasted period, driven by rising healthcare spending, the expansion of molecular diagnostic laboratories, and increased awareness of genetic and uncommon disorders. Countries such as China, Japan, and India are rapidly adopting advanced sequencing technologies, aided by government initiatives to encourage biotech innovation and genomic research. The increasing presence of domestic biotech enterprises and foreign cooperation improves technical transfer and commercial penetration.

On April 2026, Nippon Shinyaku Co., Ltd. established a collaborative agreement with xFOREST Therapeutics Co., Ltd. to develop innovative medications that target RNA structures. Under the terms of this agreement, Nippon Shinyaku will get xFOREST’s “FOREST technologies” and will work to promote the discovery and evaluation of small-molecule compounds that target RNA structures.

Europe RNA Analysis/Transcriptomics Market:

Europe is expected to register a considerable market share during the forecasted period, powered by a sophisticated healthcare infrastructure and strong regulatory frameworks that support high-quality research results. Increasing governmental and private sector investments in genomics research, coupled with a strong emphasis on personalized medicine initiatives, are propelling market growth. Countries such as Germany, the United Kingdom, and France are driving regional innovation, using modern sequencing technologies and bioinformatics tools to improve diagnostic accuracy and pharmaceutical development.

On October 2025, Plasmidsaurus, the leading global Sequencing as a Service provider, has announced the debut of a new RNA-Seq service. Plasmidsaurus is applying its novel approach to sequencing as a service to Illumina short read applications, delivering the same speed, convenience, and insights to gene expression studies that they pioneered for plasmid sequence.

Competition Analysis:

RNA analysis/transcriptomics market is characterized by a fragmented structure, with several players competing across various segments and regions. List of major players included in RNA analysis/transcriptomics market report are:

• Illumina, Inc
• Thermo Fisher Scientific Inc.
• CD Genomics
• Bio-Rad Laboratories, Inc.
• GENEWIZ Germany GmbH
• Eurofins Genomics
• QIAGEN
• Hoffmann-La Roche Ltd
• Agilent Technologies, Inc.
• BGI Genomics
• Novogene Co., Ltd.
• Evotec SE
• Bruker Spatial Biology, Inc.
• Singleron Biotechnologies
• Bio-Techne Corporation

Strategic Developments in RNA Analysis/Transcriptomics Market:

• In January 2026, SeekGene, a biotechnology company that specializes in single-cell technology platforms, has announced the availability of its innovative high-throughput single-cell DNA methylation and RNA multi-omics solution. The solution aims to simplify integrated epigenetic and transcriptomic analysis at the single-cell level, allowing for the simultaneous profiling of RNA transcriptomes, immune repertoires (TCR/BCR for immune cells), and genome-wide DNA methylation signals (5mC/5hmC) from the same single cell or nucleus.
• In November 2025, SPT Labtech has announced a collaboration with Pacific Biosciences (PacBio) to automate <strong>PacBio’s Kinnex full-length RNA-seq library preparation using SPT Labtech’s firefly liquid handling technology. The automated method will increase repeatability and scalability in large-scale transcriptomics experiments by minimizing the number of manual library preparation procedures.</span>

Key Advantages for Stakeholders:</span></h5>

Navistrat Analytics’ industry report provides an in-depth quantitative analysis of various market segments, historical and

current trends, market forecasts, and dynamics within the global market. The historical years covered in this report are 2023 to 2024, with 2025 serving as the base year for market size calculations. The forecast period extends from 2026 to 2033.

The report includes an executive summary and a comprehensive

overview of market drivers, restraints, opportunities, and challenges (DROC), along with insights into regulatory standards. It features detailed analyses such as PORTER’s Five Forces, SWOT, and PESTLE, as well as assessments of technological trends and the competitive landscape.

PORTER’s Five Forces analysis helps stakeholders evaluate the impact of new en</p>

trants, competitive rivalry, supplier power, buyer power, and substitution threats, enabling them to assess the level of competition and the attractiveness of the global market. The competitive landscape provides stakeholders with a clear understand

ing of the current market positions of key players, offering valuable insights into their competitive environment.

“font-family: arial, helvetica, sans-serif;”>Scope And Key H

ighlights Of RNA Analysis/Transcriptomics

Market Report:

>

RNA Analysis/Transcriptomics market report offers a detailed analysis of market size, including historical revenue (in USD Billion) data for 2023-2024 and revenue forecasts for 2026-2033 across the following segments:

• <strong>Product Type Outlook (Revenue, USD Billion; 2023-2033)
  • =”font-family: arial, helvetica, sans-serif;”>Instruments
    • <span style=”font-family: arial, helvetica, sans-serif;”>Sequencers
    • PCR systems
    • Microarray scanners
  • Software & Bioinformatics
    • Data analysis platforms
    • RNA expression analysis tools
  • Services
    • Sequencing services
    • CRO-based transcriptomics services

• Technology Outlook (Revenue, USD Billion; 2023-2033)
  • Next-Generation Sequencing (NGS)
  • Polymerase Chain Reaction (qPCR)
  • Microarrays
  • Digital Spatial Profiling (DSP)

• Application Outlook (Revenue, USD Billion; 2023-2033)
  • Drug Discovery & Development
  • Clinical Diagnostics
  • Biomarker Discovery
  • Toxicogenomics
  • Personalized Medicine

• End-Use Outlook (Revenue, USD Billion; 2023-2033)
  • Hospitals and Clinics
  • Pharmaceutical & Biotechnology Companies
  • Contract Research Organizations (CROs)
  • Academic & Research Institutes

• Regional Outlook (Revenue, USD Billion; 2023-2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Benelux
    • Nordic Countries
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Oceania
    • ASEAN Countries
    • Rest of APAC
  • Latin America
    • Brazil
    • Rest of LATAM
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Israel
    • Turkey
    • Rest of MEA

Frequently Asked Questions (FAQ) about RNA Analysis/Transcriptomics Market report